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Abstract
Background: Ependymal tumors in adults are rare, accounting for less than 4 % of primary tumors of the central
nervous system in this age group. The low prevalence of intracranial ependymoma in adults limits the ability to
perform clinical trials. Therefore, treatment decisions are based on small, mostly retrospective studies and the role
of chemotherapy has remained unclear.
Methods: We performed a retrospective study on 17 adult patients diagnosed with intracranial World Health
Organisation grade II or III ependymoma, who were treated with chemotherapy at any time during the disease
course. Benefit from chemotherapy was estimated by applying Macdonald criteria. Progression-free (PFS) and
overall survival (OS) were calculated from start of chemotherapy, using the Kaplan-Meier method.
Results: Eleven patients had supratentorial and 6 infratentorial tumors. Ten patients were treated with
temozolomide (TMZ), 3 with procarbazine/lomustine/vincristine (PCV), 3 with platinum-based chemotherapy and 1
patient received epirubicin/ifosfamide. Response rates were as follows: TMZ 8/10 stable disease; PCV 3/3 stable
disease; platinum-based chemotherapy 1/3 partial response; epirubicin/ifosfamide 1/1 complete response. PFS rates
at 6, 12 and 24 months were 52.9, 35.3 and 23.5 %. OS rates at 6, 12 and 24 months were 82.4, 82.4 and 70.1 %.
There was no indication for a favourable prognostic role of O6-methylguanyl-DNA-methyltransferase (MGMT)
promoter methylation which was detected in 3/12 investigated tumors.
Conclusions: Survival outcomes in response to chemotherapy in adult intracranial ependymoma patients vary
substantially, but individual patients may respond to any kind of chemotherapy. There were too few patients to
compare survival data between chemotherapeutic subgroups.
Keywords: Adults, Chemotherapy, Intracranial ependymoma, Overall survival, Progression-free survival
Background
Ependymomas are a histologically, biologically and clin-
ically heterogenous group of glial tumors that show
histological features of ependymal differentiation and
preferentially are located in the cerebral ventricles or the
spinal cord. In total, ependymomas account for 6.8 % of
all gliomas, with the relative frequency being higher in
children compared to adults [1]. In adults, ependymo-
mas are less than 4 % of primary central nervous system
tumors [2] and are found more often in spinal (46 %)
than infra- (35 %) or supratentorial (19 %) locations [3].
These tumors are classified by the World Health Organ-
isation (WHO) into 3 grades [4]. The prognostic rele-
vance of the histopathological distinction between WHO
grade II versus WHO grade III ependymomas has
remained controversial [2, 5]. In comparison to WHO
grade II ependymomas, WHO grade III ependymomas are
associated with increased risk of treatment failure [3].
The low prevalence of intracranial ependymoma in
adults limits opportunities to perform large clinical tri-
als. Thus, treatment recommendations are based on
small, mostly retrospective studies. Surgical resection is
the most important therapeutic intervention for intra-
cranial ependymomas [2]. Extent of resection has been
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associated with increased progression-free survival (PFS)
and overall survival (OS) in most series [3, 6–8]. Adju-
vant radiotherapy (RT) is recommended for patients di-
agnosed with anaplastic (WHO grade III) ependymoma
[2, 9], whereas the role of RT in patients with WHO
grade II ependymoma is discussed controversially. While
resection followed by irradiation as first-line therapy is
considered for posterior fossa ependymoma [10], RT for
supratentorial ependymoma is commonly used only
when surgical resection has been incomplete [2, 3, 11].
The role of chemotherapy (CT) for intracranial ependy-
moma in adults remains unclear. A variety of chemo-
therapeutic drugs has been investigated in the past,
mostly in retrospective studies or case reports. Selected
case reports demonstrate response to temozolomide
(TMZ) in recurrent WHO grade III ependymoma [12,
13] or recurrent WHO grade II and III ependymomas
[14]. Activity of TMZ was also described in a retrospect-
ive study, analyzing recurrent WHO grade II ependymo-
mas, refractory for platinum-based chemotherapy [15],
as well as in a prospective phase II study in ependy-
moma patients treated with TMZ and lapatinib at tumor
recurrence [16]. Brandes and colleagues compared pa-
tients with recurrent WHO grade II ependymomas
treated with cisplatin-based CT or treated with another
kind of CT, demonstrating no significant differences re-
garding PFS or OS [17]. Here we performed a retro-
spective analysis of outcome data in 17 adult patients
diagnosed with intracranial WHO grade II or III ependy-
moma and treated with chemotherapy at any time dur-
ing their disease course.
Methods
Patients and tumors
In accordance with approval from the appropriate Insti-
tutional Review Boards, the surgical specimens and clin-
ical records were retrieved from 17 patients treated at
the University Hospital Zurich, Zurich, Switzerland, or
at one of the eight University Hospitals in Germany par-
ticipating in the German Glioma Network (GGN)
(http://www.gliomnetzwerk.de). All patients gave written
informed consent according to the research proposals
approved by the Institutional Review Boards of the par-
ticipating institutions (University of Zurich, Switzerland;
Universities of Bochum, Bonn, Dresden, Düsseldorf,
Hamburg, Heidelberg, Munich and Tübingen, all
Germany). All tumors were classified and graded accord-
ing to the WHO classification of tumors of the central
nervous system [4]. The O6-methylguanyl-DNA-methyl-
transferase (MGMT) promoter methylation status was
determined by methylation-specific polymerase chain re-
action in 12 tumors [18]. Epidemiological and treatment
data were taken from patient health records. Radiological
response rates to chemotherapy were documented using
Macdonald criteria [19] as foreseen in the German Glioma
Network study protocol.
Statistics
PFS and OS curves were estimated by the Kaplan-
Meier method. PFS was calculated from the date of
first chemotherapy to the date of progression. OS was
measured from the date of first chemotherapy to the
date of death. Patients without confirmed death were
censored for OS at the last follow-up visit. Patients
without documented progression were censored at the
last follow-up visit for PFS. Survival-related analyses
were calculated with the log-rank test. A cox propor-
tional hazard model was used for univariate analysis,
to test the association of clinical predictors with sur-
vival outcomes from start of chemotherapy. All statis-
tical tests were two-tailed, and a p value of 0.05 was
set as statistically significant. All statistical analyses
were performed using Prism 6 (GraphPad Software)
or Statistics 22 (SPSS software).
Results
Patient characteristics
Table 1 summarizes the principle patient characteristics:
17 patients initially diagnosed with intracranial ependy-
moma WHO grade II or III were studied. Median age at
diagnosis was 28 years (range 18–56 years, mean age
33 years, 95 % confidence interval (CI) 27–40); 14 pa-
tients were men (82.4 %); 11 patients had supratentorial
(64.7 %) and 6 patients had infratentorial (35.3 %) tu-
mors. Most patients (58.8 %) had a Karnofsky Perform-
ance Score (KPS) of 90–100 % at the time of initial
diagnosis. At time of first chemotherapy, most patients
(52.9 %) had a KPS of 70–80 %. Histology at time of first
surgical intervention revealed ependymoma WHO grade
II in 4 patients and anaplastic ependymoma WHO grade
III in 13 patients. Nine patients were treated with RT
alone (52.9 %) as first-line therapy post-surgery, 2
patients with anaplastic ependymoma received radio-
therapy plus concomitant and maintenance temozo-
lomide chemotherapy (TMZ/RT→ TMZ) [20] at this
timepoint, while 6 patients did not receive upfront
treatment. At recurrence, 11 patients (64.7 %) under-
went another surgical tumor resection and 6 patients
(35.3 %) received CT treatment at this time. The
remaining 9 patients received the first CT treatment
at subsequent recurrences. In all cases tumor recur-
rence was local when CT was started. Three patients
(patients 7, 8 and 14) experienced spinal drop me-
tastases later on in the course of disease. Eight pa-
tients (47.1 %) were alive at a median follow-up
period of 87 months. Median follow-up, defined
from start of first chemotherapy, was 39 months for
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the whole patient group. Individual patient profiles
are summarized in Table 2.
At time of recurrence 2 patients initially diagnosed
with anaplastic ependymoma were diagnosed with
sarcoma (patient 5) or gliosarcoma (patient 9)
(Table 2). Both patients had been previously treated
with RT. At recurrence patient 5 was treated with
7 cycles of epirubicin/ifosfamide and demonstrated a
complete response (CR) with no evidence of recur-
rence during follow-up of 8.8 years. Patient 9 was
treated with 9 cycles of TMZ, best response was
Table 1 Summary of patient characteristics
n = 17 patients
Age (years)
Median 28
Range 18–56
Age classes, n (%)
≤ 20 years 2 (11.8)
21–30 years 8 (47.1)
31–40 years 0
41–50 years 5 (29.4)
> 50 years 2 (11.8)
Gender
Female 3 (17.6)
Male 14 (82.4)
KPS (pre-operative), n (%)
90–100 10 (58.8)
70–80 6 (35.3)
< 70 0
No data 1 (5.9)
KPS (start first CT), n (%)
90–100 3 (17.6)
70–80 13 (76.5)
< 70 0
No data 1 (5.9)
Tumor localizationc
Supratentorial 11 (64.7)
Infratentorial 6 (35.3)
Extent of first resection, n (%)
Gross total resection 4 (23.5)
Subtotal resection 5 (29.4)
Partial resection 5 (29.4)
Biopsy 2 (11.8)
No data 1 (5.9)
Histology (initial)
Ependymoma WHO grade II 4 (23.5)
Anaplastic ependymoma WHO grade III 13 (76.5)
Histology (start first CT)
Ependymoma WHO grade II 1 (5.9)
Anaplastic ependymoma 14 (82.4)
Sarcoma/Gliosarcoma 2 (11.8)
MGMT promoter methylation status, n (%)
Unmethylated 9 (52.9)
Methylated 3 (17.6)
No data 5 (29.1)
First-line therapies beyond surgery, n (%)
RT alone 9 (52.9)
Table 1 Summary of patient characteristics (Continued)
TMZ/RT→ TMZ 2 (11.8)
No therapy 6 (35.3)
First salvage therapy, n (%)
Re-resection
alone 4 (23.5)
plus RT alone 2 (11.8)
plus RT plus TMZ 2 (11.8)
plus Bevacizumab 1 (5.9)
plus CTa 2 (11.8)
CT aloneb 4 (23.5)
RT alone 1 (5.9)
Bevacizumab alone 1 (5.9)
First CT, n (%)
TMZ 10 (58.8)
Procarbazine plus Lomustine plus Vincristine 3 (17.6)
Epirubicin plus Ifosfamide 1 (5.9)
Carboplatin plus Etoposide 2 (11.8)
Carboplatin plus Etoposide plus Vincristine 1 (5.9)
Number of surgical interventions
1 5 (29.4)
2 3 (17.6)
> 3 9 (52.9)
Survival (from first CT) (all patients n = 17)
Median follow-up (months) 39
Median PFS (months) (95% CI) (events) 10 (3.4–16.6) (15)
Median OS (months) (95% CI) (events) 41 (31.6–50.4) (9)
Survival (from first CT)
(n = 15, patients 5 and 9 excludedd)
Median follow-up (months) 39
Median PFS (months) (95 % CI) (events) 6 (1.5–10.5) (14)
Median OS (months) (95 % CI) (events) 41 (30.0–52) (8)
CI confidence interval, CT chemotherapy, KPS Karnofsky Performance Score,
MGMT O6-methylguanyl-DNA-methyltransferase, n.a. not applicable, OS overall
survival, PCV procarbazine/lomustine/vincristine, PFS progression-free survival,
RT radiotherapy, TMZ temozolomide
a, 1 PCV, 1 TMZ; b, 1 PCV, 2 TMZ, 1 carboplatin plus etoposide; c, tumor
localization was the same at date of diagnosis and start of CT; d, patients 5
and 9 were diagnosed with sarcoma or gliosarcoma at recurrence
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Table 2 Individual patient characteristicsc
No. Initial
histology
WHO
grade
MGMT
status
Localization Extent of
resection
First-line
therapy
First salvage
therapy
Surgical
interventions (n)
Histology at
start of CT
First CT Duration of
first CT a
Best
response
DBRa PFSa OSa
P1 E II unmethyl. infratentorial subtotal - RT 3 AE TMZ 11 SD 11 17 68b
IV ventricle
P2 E II unmethyl. supratentorial partial RT re-resection RT >3 AE PCV 18 SD 4 21 41
parietal
P3 E II unmethyl. infratentorial partial - re-resection 2 AE TMZ/RT→TMZ 8 SD 29 32b 32b
cerebellar TMZ/RT→TMZ
brainstem
IV ventricle
P4 E II unmethyl. supratentorial partial - re-resection 3 E TMZ 6 SD 2 5 5
III ventricle
P5 AE III n.d. supratentorial gross total RT re-resection 2 sarcoma epirubicin 5 CR 106 131b 131b
parietal ifosfamide
temporal
occipital
P6 AE III unmethyl. infratentorial subtotal RT carboplatin 1 AE carboplatin 5 PR 7 11 16b
IV ventricle etoposide etoposide
P7 AE III n.d. supratentorial partial - re-resection >3 AE carboplatin 1 PD - 2 44b
parietal etoposide
vincristine
cyclo-
phosphamide
P8 AE III unmethyl. infratentorial gross - re-resection >3 AE TMZ 17 SD 21 25 80b
IV ventricle total RT
P9 AE III n.d. supratentorial biopsy RT re-resection 3 gliosarcoma TMZ 9 SD 7 10 23
frontal TMZ
temporal
P10 AE III n.d. infratentorial gross RT TMZ 1 AE TMZ 5 SD 31 33 101b
cerebellar total
P11 AE III unmethyl. supratentorial subtotal RT TMZ 1 AE TMZ 9 SD 9 10 13
III ventricle
P12 AE III n.d. supratentorial subtotal TMZ/RT→
TMZ
re-resection >3 AE TMZ/RT→ TMZ 5 SD 4 5 48
parietal bevacizumab
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Table 2 Individual patient characteristicsc (Continued)
P13 AE III unmethyl. supratentorial gross total RT re-resection 3 AE PCV 8 SD 1 5 40
parietal PCV
P14 AE III unmethyl. supratentorial biopsy - re-resection 2 AE TMZ 1 PD - 2 2
temporal RT
III ventricle TMZ
P15 AE III methyl. infratentorial partial RT re-resection 3 AE carboplatin n.d. PD - 4 29b
cerebellar etoposide
brainstem
IV ventricle
P16 AE III methyl. supratentorial n.d. RT PCV 1 AE PCV 3 SD 2 6 39
temporal
P17 AE III methyl. supratentorial subtotal TMZ/RT→
TMZ
bevacizumab 1 AE TMZ/RT→ TMZ 1 PD - 1 6
parietal
AE anaplastic ependymoma, CR complete response, DBR duration best response, E ependymoma WHO grade II; unmethyl., unmethylated, MGMT status O6-methylguanyl-DNA-methyltransferase promoter methylation
status, n.d. no data, no. number, OS overall survival, P patient, PCV procarbazine/lomustine/vincristine, PD progressive disease, PFS progression-free survival, PR partial response, RT radiotherapy, SD stable disease,
TMZ temozolomide
a in months; b indicates patients who did not demonstrate progressive disease decease or who were not deceased, c median age was 28 years (range 18–56), 3 female and 14 male patients were included
G
ram
atzkiet
al.BM
C
Cancer
 (2016) 16:287 
Page
5
of
12
stable disease (SD) with PFS of 10 months and OS
of 23 months.
Benefit from chemotherapy
At time of first chemotherapeutic treatment, 10 patients
were treated with TMZ (58.8 %), 3 patients with procar-
bazine/lomustine/vincristine (PCV) (17.6 %), 3 patients
with platinum-based CT (carboplatin/etoposide (11.8 %)
or carboplatin/etoposide/vincristine (5.9 %)) and 1 patient
with epirubicin/ifosfamide (5.9 %) (Table 1). Two patients
received CT as first line therapy, 8 patients at time of
first recurrence and 7 patients at time of second recur-
rence (Table 2). Median PFS after first chemotherapeu-
tic treatment was 10 months (95 % CI 3.4–16.6) for
all patients pooled, as it was for the group of patients
treated with TMZ (95 % CI 2.4–17.6); it was 4 (95 %
CI 0.8–7.2) months for patients treated with
platinum-based CT and 6 months (95 % CI 4.4–7.6)
for patients treated with PCV. PFS for the patient
treated with epirubicin/ifosfamide was not reached
during a follow-up period of 131 months. Median OS
from start of chemotherapy was 41 months (95 % CI
31.6–50.4) for all patients pooled, 23 months (95 %
CI 0–71.2) for patients treated with TMZ and
40 months (95 % CI 38.4–41.6) for patients treated
with PCV. OS in the group of patients treated with
platinum-based CT was not reached during the
follow-up period. Since two patients (patients 5 and
9), treated with epirubicin/ifosfamide or TMZ, were
not diagnosed with classical ependymoma at time of
start of chemotherapy, survival data were also
assessed for the remaining 15 patients: median PFS
after first chemotherapeutic treatment was 6 months
(95 % CI 1.5–10.5) for all patients pooled (n = 15),
and 10 months (95 % CI 0.0–24.6) for patients
treated with TMZ; median OS after first chemothera-
peutic treatment was 41 months (95 % CI 30.0–52)
for all patients pooled (n = 15), and 48 months (95 %
CI 0.0–133.4) for patients treated with TMZ. In the
group of patients treated with TMZ, 8 patients
showed SD and 2 patients showed progressive disease
(PD). In the group of patients treated with PCV, all 3
patients had SD and among the 3 patients treated
with platinum-based CT, 1 patient demonstrated par-
tial response (PR) and 2 patients PD. The patient
who received epirubicin/ifosfamide (patient 5) demon-
strated CR (Table 2). PFS and OS for all patients are
shown in Fig. 1. PFS rates at 6, 12 and 24 months
were 52.9, 35.3 and 23.5 % for all 17 patients in-
cluded in this study, and 46.7, 33.3 and 33.3 % when
the two patients diagnosed with sarcoma or gliosar-
coma at time of recurrence were excluded. OS rates
at 6, 12 and 24 months were 82.4, 82.4 and 70.1 %
for all patients, and 80.0, 80.0 and 73.3 % for the
reduced patient cohort (n = 15). Group sizes were too
small for formal comparisons, but not obvious signal
of activity of a particular regimen became apparent.
MGMT promoter methylation and survival in intracranial
ependymoma
The MGMT promoter methylation status of the tumor
was available in 12 patients (Table 2): 3 patients had
MGMT promoter methylated tumors, whereas 9 patients
did not. Patients with MGMT promoter methylated
tumors were treated with TMZ, platinum-based CT or
PCV. Patients without MGMT promoter methylation
were treated with TMZ (6 patients), platinum-based CT
(1 patient) or PCV (2 patients). Median PFS was
4 months for patients with MGMT promoter methylated
tumors and 11 months for patients with MGMT pro-
moter unmethylated tumors. Median OS was 39 months
for patients with MGMT promoter methylated tumors
versus 40 months for patients with MGMT promoter
Fig. 1 Outcome in ependymoma patients. Kaplan-Meier survival
curves of PFS (a) and OS (b) after chemotherapy are shown for all
17 patients, initially diagnosed with ependymoma (black line) or for
the 15 patients, diagnosed with ependymoma at time of start CT
(grey line); the two patients excluded for the second analysis were
initially diagnosed with ependymoma, but diagnosed with sarcoma
or gliosarcoma at time of recurrence
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unmethylated tumors. Group sizes were too small for
formal comparisons between patients stratified accord-
ing to the MGMT promoter methylation status.
Association of age, tumor localization, gender, KPS and
MGMT promoter methylation status with survival
Patients were divided into two groups, defined by age,
tumor localization, gender, KPS and MGMT promoter
methylation status, and a log-rank survival analysis was
performed. This analysis revealed supratentorial tumors
to be associated with inferior survival (Table 3, Add-
itional file 1: Table S1). Univariate analysis using the cox
proportional hazard model from start of first CT treat-
ment was performed to identify factors associated with
overall survival. The results of these analyses are sum-
marized in Table 3 for all 17 patients initially diagnosed
with ependymoma, and in Additional file 1: Table S1 for
the remaining patient cohort when the two patients di-
agnosed with sarcoma or glioblastoma at recurrence
were excluded. Age, tumor localization, gender, KPS and
the MGMT promoter methylation status were not iden-
tified as risk factors for death in both patient cohorts
(Table 3, Additional file 1: Table S1).
Discussion
Intracranial ependymoma is a rare disease in adults [2].
While the role of surgical resection and RT for tumor
control is undisputed [2, 3, 6–9, 11], little is known
about the significance of CT. Here we retrospectively
analyzed 17 adult patients with intracranial WHO grade
II or grade III ependymomas to investigate the impact of
chemotherapy on the disease course.
Most patients (n = 10) received TMZ as their first che-
motherapeutic treatment (Table 1). Two of these pa-
tients received a combined treatment of irradiation and
TMZ (TMZ/RT→TMZ) [20] at diagnosis. Median PFS
for these two patients was low with 3 months as it was
for median OS with 27 months. The other 8 patients
were treated with TMZ at recurrence and the best re-
sponse was SD. Thus, TMZ demonstrated some activity
in intracranial ependymoma patients, especially at time
of recurrence. Of note, there is one prospective study
presented at the American Society of Clinical Oncology
(ASCO) in 2005, which included patients with recurrent
WHO grade II and III ependymomas. Activity of TMZ
treatment in these patients was as follows (best re-
sponse: median PFS): CR (n = 2): 9–48 months; PR (n =
3): 4–15 months; SD (n = 5): 7–44 months [14] (Table 4).
Less optimal results were reported by Chamberlain and
Johnston for TMZ treatment of 25 patients with recur-
rent WHO grade II ependymomas, refractory to
platinum-based chemotherapy, who demonstrated a me-
dian PFS of 3 months, and best responses of PR in 1
patients and SD in 9 patients with a median OS of
3 months [15] (Table 4). Moreover, results of a
prospective trial, including 24 patients diagnosed with
WHO grade II ependymoma and 18 patients diagnosed
with anaplastic ependymoma, treated with TMZ plus
Table 3 Association of age, tumor localization, gender, KPS and MGMT promoter methylation status with survival
(all patients, n = 17)
Variable Number of patients
(events)
Median OS (months)
(95 % CI)
p value
(log-rank)
p value
(cox regression)
Hazard Ratio
(95 % CI)
Agea
< 40 years 9 (5) 48 (28.5–67.5) 1
≥ 40 years 8 (4) 41 (13.8–68.14) 0.587 0.589 1.45 (0.37–5.64)
Tumor localizationa
Infratentorial 6 (0) undefined 1
Supratentorial 11 (9) 39 (9.87–68.13) 0.011 (*) 0.163 50.8 (0.20–12662.82)
Gender
Female 3 (2) 41 (0–97.01) 1
Male 14 (7) 48 (35.84–60.16) 0.888 0.888 0.89 (0.18–4.34)
KPSa
100–80 11 (6) 48 (14.47–81.54) 1
< 80 5 (3) 41 (11.96–70.04) 0.872 0.872 1.12 (0.28–4.52)
MGMT promoter methylation
not methylated 9 (5) 40 (9.3–70.7) 1
methylated 3 (2) 39 (undefined) 0.433 0.443 2.02 (0.34–12.2)
CI confidence interval, KPS Karnofsky Performance Score, WHO World Health Organisation
*, p < 0.05
a, variables were determined at start of chemotherapy
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Table 4 Review of the literature: chemotherapeutic treatment regimens in adult intracranial ependymoma
First author,
year [Ref]
Trial design Patient
diagnosis, n
Tumor
localization
Treatment
regimen, n
Response
rates, n
Median PFS,
after start CT
Median OS,
after start CT
present
study
Retrospective newly diagnosed
and recurrent
WHO grade II
and III
ependymoma, 17
supratentorial or
infratentorial
TMZ-based CT: 10 CR: 1 10 months 41 months
platinum-based CT: 3 PR: 1
PCV: 3 SD: 11
epirubicin/ifosfamide: 1
(no prior CT)
PD: 4
Gilbert
et al.,
2014 [16]
Prospective recurrent WHO
grade II
ependymoma,
24 and grade III,
18 ependymoma
intracranial
and/or spinal
TMZ plus lapatinib WHO grade II WHO-grade II: 45 weeks -
PR: 2 WHO-grade III:
25.3 weeks
SD/PD: no
data
WHO grade III
CR: 1
PR: 1
SD/PD: no
data
Chamberlain
and Johnston,
2009 [15]
Retrospective recurrent WHO
grade II
ependymoma, 25
supratentorial TMZ
(after platinum-based CT)
PR: 1 2 months 3 months
SD: 9
PD: 15
Green
et al.,
2009 [26]
Retrospective recurrent WHO
grade II and III
ependymoma, 8
supratentorial
or infratentorial
bevacizumab
(after platinum-based CT or TMZ)
PR: 6 6.4 months 9.4 months
SD: 1
PD: 1
Brandes
et al.,
2005 [17]
Retrospective recurrent WHO
grade II and III
ependymoma, 28
intracranial cisplatin-based CT: 13
(no prior CT)
CR: 2 9.9 months 31 months
PR: 2
SD: 7
PD: 2
versus versus versus versus
CT without cisplatin: 15
(no prior CT)
PR: 2 10.9 months 40.7 months
SD: 11
PD: 2
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Table 4 Review of the literature: chemotherapeutic treatment regimens in adult intracranial ependymoma (Continued)
Soffietti
et al.,
2005 [14]
Prospective recurrent WHO
grade II and III
ependymoma, 11
intracranial TMZ
(some after nitrosourea or platinum-based CT)
CR: 2 CR: 9–48+ months -
PR: 3 PR: 4–15+ months
SD: 5 SD: 7–44+ months
PD: 1
Lombardi
et al.,
2013 [13]
case report recurrent anaplastic
ependymoma
supratentorial TMZ plus cisplatin
(after platinum-based CT alone and TMZ alone)
PR 9 months 11 months
Freyschlag
et al.,
2011 [12]
case report recurrent anaplastic
ependymoma
supratentorial TMZ no evidence of
radiographic
progression
5+ months -
Rojas-Marcos
et al.,
2003 [25]
case report recurrent anaplastic
ependymoma
infratentorial (initial)
and supratentorial
(at recurrence)
tamoxifen plus isotretinoin
(after TMZ, platinum-based CT, CCNU)
CR 17 months -
CR complete response, CT chemotherapy, n number of patients, OS overall survival, PCV procarbazine/lomustine/vincristine, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease,
TMZ temozolomide
+ indicates patients who did not demonstrate progressive disease
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lapatinib, were presented at the annual meeting of the
Society of Neurooncology (SNO) in 2014 [16]. Lapatinib
targets the epidermal growth factor receptor (ErbB1)
and the related family member HER-2/neu (ErbB2) on
the cell surface of the tumor cells. Median PFS was
45 weeks for patients diagnosed with grade II, and
25.3 weeks for patients diagnosed with grade III ependy-
momas. Best response rates were CR in one patient diag-
nosed with anaplastic astrocytoma and PR in 1 patient
diagnosed with anaplastic astrocytoma and 2 patients di-
agnosed for ependymoma WHO grade II. Several pa-
tients showed at least SD. First results of a molecular
classification revealed a correlation of response with
ErbB2 expression [16]. In addition, there are two case
reports of patients diagnosed with recurrent anaplastic
ependymoma, describing a median PFS after TMZ treat-
ment of 5 and 9 months [12, 13] (Table 4). One reason
for the possible failure of TMZ in patients with intracra-
nial glioma is a non-methylated MGMT promoter [21].
Ependymomas may express high levels of MGMT [22],
predicting less benefit from TMZ-based CT. Only 3 out
of 12 ependymoma patients included in our study had
tumors with a methylated MGMT promoter. Median
PFS in these 3 patients was in the range of 1–6 months
and thus low, and one of these patients treated with
TMZ demonstrated no response. Our small dataset fails
to indicate a favorable prognostic role of MGMT pro-
moter methylation in adult ependymoma.
The other chemotherapeutic regimens were platinum-
based CT (n = 3) or PCV (n = 3), showing a median PFS
of 4 or 6 months and response rates as follows: PR (1
patient) or SD (3 patients) (Table 2). Brandes et al. pub-
lished a retrospective study in 2005, analyzing 28 epen-
dymoma patients (WHO grade II and III); 13 patients
were treated with platinum-based CT, demonstrating
best responses of 2 CR, 2 PR and 7 SD, and a median
PFS of 9.9 months in comparison to 15 patients treated
with CT without cisplatin, demonstrating best responses
of 2 PR and 11 SD, and a median PFS of 10.9 months
[17]. PFS data were similar to the data reported here. Al-
though response rates were lower in the group of pa-
tients treated with any other CT, but without cisplatin,
survival curves (PFS and OS) did not differ. Three of the
15 patients were treated with PCV, showing best re-
sponses with 1 PR, and 2 SD, therefore demonstrating a
similar response as reported here (Tables 2 and 4).
Beyond these mentioned standard chemotherapeutic
drugs, there is need for patient stratification based on
molecular markers to identify ependymoma subgroups
as well as subgroup-specific therapies, as recently de-
scribed by Pajtler et al. [23]. Since all pre-clinical in vivo
models tested for chemotherapy so far showed only re-
duced sensitivity towards these standard chemothera-
peutic drugs, targeted therapies (e.g. epidermal growth
factor receptor (EGFR) inhibitors, histone deacetylase
(HDAC) inhibitors) are in the focus of research at the
moment and need to be investigated [24].
Review of the literature showed a case report demon-
strating a CR and a median PFS of 17 months in an
adult patient with recurrent anaplastic intracranial epen-
dymoma after treatment with tamoxifen and isotretinoin
[25]. Beyond classical CT, Green et al. reported outcome
data in 8 recurrent WHO grade II and III intracranial
ependymomas which were treated with bevacizumab at
time of recurrence. Promising response rates with 6 PR
and 1 SD and a median PFS of 6.4 and OS of 9.4 months
were described [26].
Two patients in our study were initially diagnosed with
anaplastic ependymoma and at recurrence demonstrated
sarcoma or gliosarcoma (Table 2). Both patients had
been treated with RT in-between and had supratentorial
tumors. A common origin for the initial and the recur-
rent tumor has to be considered, since there are reports
in the literature demonstrating identical genetic muta-
tions in both glial and sarcomatous compartments of
gliosarcomas [16, 27, 28]. Interestingly, both patients ap-
peared to derive benefit from chemotherapy.
Kaplan-Meier survival analysis revealed supratentorial
tumor location as a parameter associated with inferior
survival (Table 3). Supratentorial tumor localization
has been described as significantly increasing risk of
early death [29], therefore underlining the clinical ag-
gressiveness of supratentorial ependymomas in adults
that is independent from CT treatment. Our data sug-
gest that survival outcomes in response to chemother-
apy in adult intracranial ependymoma patients vary
substantially, but individual patients may respond to
any kind of chemotherapy.
Conclusions
The main limitation of our study is its retrospective de-
sign and the low number of patients in each chemother-
apeutic subgroup. In summary, this retrospective study
provides data supporting activity of TMZ in recurrent
anaplastic ependymoma; however, there are also promis-
ing response rates in patients treated with platinum-
based CT or PCV. Because of the notably individual sur-
vival outcomes after chemotherapeutic treatment in
adult ependymoma patients with intracranial disease,
prospective studies are urgently needed to identify pa-
tient subgroups that will benefit from individual chemo-
therapeutic treatments. Yet, this report suggests that at
least one line of CT should be offered to ependymoma
patients who are no longer candidates for surgery or RT.
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